Wall Street Analysts Believe GENEDX HOLDINGS (WGS) Could Rally 77.81%: Here's is How to Trade
The consensus price target hints at a 77.8% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GeneDx: The Growth Story Isn't Dead, It's Changing (Rating Upgrade)
GeneDx (WGS) is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Per my DCF model, WGS now targets 25% CAGR and 10% free cash flow margins, with potential to reach 14% FCF margin, making its valuation less stretched. Management plans to nearly triple its commercial footprint in 2026, prioritizing growth capture over near-term margins and signaling a ramp toward 2027 acceleration.
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.7 per share a year ago.
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum
GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exceed it sufficiently for a high multiple stock, resulting in a pullback. Company's 2026 guidance was strong and above expectations with testing volume growth of 33-35%.
GeneDx Partners With Komodo Health to Advance Rare Disease Research
WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2025 Earnings Conference Call.
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The AAP's new recommendations and NIH funding position WGS for significant market expansion, with insurance coverage supporting sustainable, recurring revenue.
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseases faster and more accurately than ever before.
Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?
GeneDx Holdings Corp. (WGS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, WGS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
